Aethlon Subsidiary Exosome Sciences Collaborates with Boston University School of Medicine in Study Quantitating Exosomes That Can Carry Tau Protein Across the Blood-Brain Barrier; Part of DETECT Study of Biomarkers for CTE Looks at 78 Former NFL Players

In an April 16, 2015 press release, Aethlon Medical, Inc. (OTCQB:AEMD, AEMDD) (, a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced that Dr. Robert Stern, Professor of Neurology, Neurosurgery, and Anatomy and Neurobiology at Boston University School of Medicine (BUSM) has presented preliminary, unpublished findings related to research being conducted by Aethlon Medical's majority-owned subsidiary, Exosome Sciences, Inc. ( . The presentation was given on Apriol 16, 2015, at the 5th Annual Traumatic Brain Injury Conference that was held in Washington, D.C. The findings are part of the Diagnosing and Evaluating Traumatic Encephalopathy Using Clinical Tests (DETECT) study, a research project funded by the National Institutes of Health (NIH), being conducted at BUSM's CTE Program. The DETECT study examines potential biomarkers for CTE (chronic traumatic encephalopathy) by studying a sample of former professional American football players and a control group of same-age men without any history of brain trauma from contact sport involvement. In connection with the DETECT study, researchers at Exosome Sciences have been applying proprietary techniques to isolate microscopic exosomes that transport CTE-associated tau protein (tausomes) across the blood-brain barrier. As part of the DETECT project at BUSM, blood samples from 78 former NFL players and 16 control subjects were analyzed by Exosome Sciences researchers. In the study, researchers were able to isolate and quantify the presence of tausomes in the blood. During his presentation, Dr. Stern reported that former NFL players' tausome levels were measured to be significantly higher than those of the control subjects.
Login Or Register To Read Full Story